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Mechanical and Metabolic Injury to the Skin
Barrier Leads to Increased Expression of Murine
b-Defensin-1, -3, and -14
Kerstin Ahrens1, Michael Schunck1, Graziella-Francesca Podda1, Josef Meingassner2, Anton Stuetz2,
Jens-Michael Schro¨der1, Ju¨rgen Harder1 and Ehrhardt Proksch1
Protection of the skin against microbiological infection is provided by the permeability barrier and by
antimicrobial proteins. We asked whether the expression of murine b-defensins (mBDs)-1, -3, and -14—
orthologs of human b-defensins hBD-1, -2, and -3, respectively—is stimulated by mechanically/physicochemi-
cally (tape stripping or acetone treatment) or metabolically (essential fatty acid–deficient (EFAD) diet) induced
skin barrier dysfunction. Both methods led to a moderate induction of mBD-1 and mBD-14 and a pronounced
induction of mBD-3 mRNA. Protein expression of the mBDs was increased as shown by immunohistology and
by western blotting. Artificial barrier repair by occlusion significantly reduced the increased expression of mBD-
14 after mechanical injury and of all three mBDs in EFAD mice, supporting an interrelationship between
permeability and the antimicrobial barrier. mBD-3 expression was stimulated in vitro by tumor necrosis factor-a
(TNF-a), and a neutralizing anti-TNF-a antibody significantly reduced increased mBD-3 expression after barrier
injury in mouse skin, indicating that induction of mBD-3 expression is mediated by cytokines. The expression of
mBD-14 was stimulated by transforming growth factor-a and not by TNF-a. In summary, we demonstrated
upregulation of mBD1, -3, and -14 after mechanically and metabolically induced skin barrier disruption, which
may be an attempt to increase defense in the case of permeability barrier dysfunction.
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INTRODUCTION
The skin is constantly exposed to a variety of microbial
challenges. The permeability barrier, localized in the stratum
corneum, is a mechanical protective barrier against bacterial
infection. Impairment of the physical barrier by injury is a
prerequisite for experimental skin infection by application of
a bacterial suspension (Singh et al., 1971). In eczema or
psoriasis—skin diseases accompanied by disturbed perme-
ability barrier function—the skin is colonized with potentially
pathogenic microorganisms (Aly et al., 1976, 1977). It is well
known in clinical dermatology that occlusive conditions in
the skin body folds and the use of occlusive latex gloves and
shoes can cause hyperhydration and skin irritation (Denda
et al., 1998). Irritation results in impaired barrier function,
which in turn predisposes to skin infections such as intertrigo,
impetigo, and tinea (Warner et al., 2003; Fluhr et al., 2005).
Despite an impaired permeability barrier and significant
bacterial colonization, psoriatic skin is usually free of infection.
In atopic dermatitis, clinical signs of bacterial infection are
predominantly found in severe cases or after extensive
scratching (Lu¨bbe, 2003). Therefore, additional defense me-
chanisms besides the physical barrier have been suggested,
leading to the discovery of antimicrobial peptides produced by
epithelial cells (reviewed by Ganz and Lehrer, 1994; Gallo and
Huttner, 1998; Schro¨der, 1999; Schro¨der and Harder, 1999;
Harder and Schro¨der, 2005a, b; Izadpanah and Gallo, 2005).
Several types of antimicrobial peptides, including b-defensins,
cathelicidin (Gallo et al., 1997), catestatin (Radek et al., 2008),
RNase-7 (Harder and Schro¨der, 2002), and psoriasin (Gla¨ser
et al., 2005), have been identified in the skin. In addition, three
human b-defensins (hBD-1, -2, and -3) with a specific spectrum
of antimicrobial activity have been characterized in human
skin and are expressed in keratinocytes (Harder et al., 1997,
2001). Constitutive expression of hBD-1 has been detected in
human skin (Fulton et al., 1997; Ali et al., 2001), but its role in
cutaneous defense is still emerging because of a lack of the
respective studies. In contrast, hBD-2 and hBD-3 were
originally isolated in native form from psoriatic scale extracts
(Harder et al., 1997, 2001), and both peptides are inducibly
expressed in keratinocytes. The expression of hBD-2 and hBD-
3 can be upregulated by bacteria as well as endogenous
mediators such as cytokines (e.g., IL-1b and IL-17 for hBD-2)
and growth factors (e.g., transforming growth factor-a (TGF-a)
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for hBD-3) (Schro¨der and Harder, 1999; Sørensen et al., 2003;
Pazgier et al., 2006; Yin et al., 2006). In addition, it has been
reported that hBD-3 is induced upon epidermal injury,
suggesting a role for hBD-3 in wound healing (Sørensen
et al., 2006). Moreover, it has been documented that hBD-3 as
well as hBD-2 stimulates keratinocyte migration, proliferation,
and production of proinflammatory cytokines and chemokines
(Niyonsaba et al., 2007).
To further elucidate the role of b-defensins after epidermal
barrier disruption, we aimed to study the role of b-defensins in
a mouse model using mechanical/physicochemical (via tape
stripping or acetone treatment) as well as a metabolic (via
essential fatty acid–deficient (EFAD) diet) disruption of the skin
barrier. We focused on the expression of mouse orthologs of
the human b-defensins hBD-1, -2, and -3. Mouse b-defensin-1
(mBD-1) is the ortholog of hBD-1 (Huttner et al., 1997;
Morrison et al., 1998), but its expression in mouse keratino-
cytes has not yet been investigated. Mouse b-defensin-3
(mBD-3) is considered an ortholog of hBD-2 (Morrison et al.,
2003). mBD-3 is expressed in epithelia, especially in the lung
and gastrointestinal tract, and its expression is induced by
Pseudomonas aeruginosa (Bals et al., 1999). Expression and
induction of mBD-3 in mouse skin after barrier disruption and
by UVB exposure have recently been described (Aberg et al.,
2007, 2008; Hong et al., 2008). Synthetic mBD-3 inhibited
the growth of Escherichia coli, P. aeruginosa, Staphylococcus
aureus, and Candida albicans at concentrations from 25 to
50mgml1 (Burd et al., 2002). Recently, mouse b-defensin-14
(mBD-14) has been identified as the ortholog of hBD-3
(Hinrichsen et al., 2008; Ro¨hrl et al., 2008; Taylor et al.,
2008). mBD-14 exhibited a broad spectrum of potent
antimicrobial activity against various microorganisms, includ-
ing Gram-positive and Gram-negative bacteria and the yeast
C. albicans (Hinrichsen et al., 2008).
Both the permeability barrier and the antimicrobial barrier
are regulated by specific signaling mechanisms, including
cytokines and growth factors (Sørensen et al., 2003, 2005).
Oren et al. (2003) showed that hBD-2 is localized in epidermal
lamellar bodies and that IL-1a stimulates movement from the
endoplasmatic reticulum to lamellar bodies (post-transcrip-
tional). We and others previously described an important role
for proinflammatory cytokines in the regeneration of the
physical barrier (Wood et al., 1992; Jensen et al., 1999). Also,
a role for tumor necrosis factor-a (TNF-a) in the induction of
hBD-2 has been described (Harder et al., 1997; Varoga et al.,
2004). Cytokines and growth factors, which are necessary for
the potential induction of b-defensins during barrier repair in
mouse skin, are only partly known. In the present study, we
observed that mBD-1, -3, and -14 are upregulated by
mechanical/physicochemical as well as metabolic barrier
injury in mouse skin in vivo, and we present evidence that
cytokines and growth factors are involved in this process.
RESULTS
Mechanical/physicochemical barrier injury induces expression
of mBD-1, -3, and -14
The major goal of our study was to assess a potential
interaction between the permeability barrier and the anti-
microbial barrier and whether acute and chronic disruption
of the physical skin barrier induces changes in the
antimicrobial barrier. We performed mechanical injury to
the skin barrier through repeated tape stripping of the
skin of shaved BALB/c mice, which potentially leads to an
invasion of environmental germs into the living epidermal
layers. Subsequently we examined mRNA and protein
expression of mBD-1, -3, and -14 at different time points
after barrier disruption. mRNA levels revealed a significant,
slight increase in mBD-1 and mBD-14 expression 6 hours
after barrier disruption as well as a significant, pronounced
increase of mBD-3 expression. At 16 hours after barrier
disruption, a very slight but significant increase in the
mRNA expression could be detected only for mBD-14
(Figure 1a).
mBD-1 protein immunostaining in untreated skin was
visible in granular and spinous layers (Figure 1b). A moderate
increase in staining density occurred at 4–48 hours after
barrier injury, especially in granular layers, and staining also
involved spinous and basal layers. For mBD-3, only faint
staining was detected in untreated skin, which was concen-
trated in basal and spinous layers (Figure 1b). Staining
strongly increased at 4–48 hours after skin barrier disruption.
Immunoreactivity for mBD-3 was visible in the entire
nucleated epidermis with slightly higher staining density in
granular layers. Staining for mBD-14 was already moderate in
untreated skin, concentrated in granular layers, and also
visible in spinous and basal layers (Figure 1b). At 4–48 hours
after injury of the skin barrier, the staining of mBD-14 protein
increased as seen for mBD-1 and -3.
Occlusion partially reduced expression of mBD-1, -3, and -14
after barrier injury
In previous studies, artificial skin barrier repair reduced the
expression of several, but not all, metabolic events in the skin
induced by skin barrier disruption (Proksch et al., 1990;
Wood et al., 1994). For technical reasons, we used hairless
SKH-1 mice—a tight fit of the occlusive foil (with the thumb
of a latex glove used as a tube) was more easily obtained than
with shaved hairy mice. We used acetone treatment as well
as tape stripping for barrier disruption. However, we show
occlusion data only for acetone-induced barrier disruption
because tape stripping yielded a high variance in mRNA
expression (data not shown). After acetone-induced barrier
injury, we found a significant but moderate increase in mBD-
1 and -14 expression and a significant, pronounced increase
in mBD-3 mRNA expression (Figure 2a). However, the
increase in mRNA expression, especially for mBD-1 and
mBD-14, was more pronounced after acetone treatment
compared with tape stripping. Occlusion for 24 hours after
acetone treatment reduced mRNA expression of the investi-
gated b-defensins significantly for mBD-14—however, not to
normal levels (Figure 2a).
Immunohistology revealed increased staining. A reduced
increase in staining intensity, in particular for mBD-14,
occurred with occlusion (Figure 2b). Western blotting
revealed an increased protein expression for mBD-1, -3,
and -14 after barrier injury in SKH-1 mice (Figure 2c).
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Metabolically induced barrier dysfunction–induced expression
of mBD-1, -3, and -14
Mice fed an EFAD diet develop a red and scaly skin, impaired
epidermal differentiation, a disturbed skin barrier function,
and increased bacterial colonization (Bibel et al., 1989;
Proksch et al., 1992). In the present study, transepidermal
water loss as a marker of skin barrier function increased from
9.0±0.35 to 26.9±1.15 gm2 per hour (n¼ 10, Po0.005).
An EFAD diet resulted in a significantly increased mRNA
expression of all analyzed b-defensins (Figure 3a).
Immunostaining for mBD-1 was increased in the skin of
EFAD mice compared with untreated mice; it was clearly
visible in the entire nucleated epidermis and concentrated in
the granular layer. Immunostaining for mBD-3 also in-
creased. Highest staining density was found in the granular
layers and less pronounced in the granular layer. An
increased staining intensity occurred for mBD-14. Staining
was most pronounced in the granular layer (Figure 3b).
Western blotting revealed an increased protein expression for
all mBDs (Figure 3c).
Occlusion reduced expression of mBD-1, -3, and -14 in
metabolically induced skin barrier dysfunction
Occlusion by latex foil for 48 hours significantly reduced the
EFAD-induced increased mRNA expression for mBD-1, -3,
and -14 (Figure 3a). Similarly, mBD staining intensity in
immunohistology was reduced (Figure 3b).
mBD-3 expression was stimulated by TNF-a and mBD-14
expression was stimulated by TGF-a in mouse keratinocyte
culture in vitro
After mechanical/physicochemical barrier injury by tape
stripping or acetone treatment, inflammatory processes take
place with expression of different cytokines and growth
factors (Wood et al., 1992; Jensen et al., 1999; Werner et al.,
2007). To evaluate whether inflammatory reactions may
affect b-defensin expression, we stimulated primary mouse
keratinocytes with the proinflammatory cytokine TNF-a and
with TGF-a. Concentrations of 10 ngml1 for TNF-a and
50 ngml1 for TGF-a proved to be most effective. TNF-a
induced the expression of mBD-3 mRNA 16hours after
treatment (Figure 4a). mBD-14 mRNA expression was
induced by TGF-a 24 hours after treatment (Hinrichsen
et al., 2008). This correlated with an induction of mBD-14
protein secretion after 24 hours as measured by ELISA
(Figure 4b).
Injection of a neutralizing anti-TNF-a antibody led to reduced
expression of mBD-3 after barrier injury
To examine whether the stimulation of mBD-3 expression
by TNF-a is relevant for an in vivo situation, we intraper-
itoneally injected a neutralizing anti-TNF-a antibody in mice
24 hours before physicochemical barrier injury (Plessner
et al., 2007). A significant reduction in mBD-3 mRNA
expression occurred 6 hours after barrier disruption.
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Figure 1. Expression of mouse b-defensins (mBDs) is enhanced in skin after barrier injury caused by tape stripping. (a) Stratum corneum barrier injury in
BALB/c mice caused an increase in mBD-1, -3, and -14 mRNA expression 6 hours after barrier injury. Relative mRNA expression was quantified by real-time
PCR (columns represent means±SE; *Po0.05; n¼ 8–11). (b) Immunohistochemical staining in mouse skin showed expression of mBD-1, -3, and -14 in the
suprabasal epidermis. At 6 hours after barrier injury an increase in staining density for mBD-1, -3, and -14 occurred. Staining of all three b-defensins extended
to the basal layer and was most pronounced in the granular layer. Bars ¼ 50 mm.
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A similar trend was noted for mBD-1 and mBD-14 mRNA
expression (Figure 5a).
Similar results were observed at the protein level
investigated by immunohistochemistry (Figure 5b).
DISCUSSION
The skin is permanently exposed to a variety of potentially
harmful microorganisms but usually remains free of
infection. An intact permeability barrier prevents infection.
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Figure 2. Expression of mouse b-defensins (mBDs) is induced after barrier injury by acetone treatment and can be reduced by occlusion. (a) Stratum
corneum barrier injury by acetone treatment led to an increased expression of mBD-1, -3, and -14 in SKH-1 mice 6hours after barrier injury. The increase was
reduced by application of an occlusive foil immediately after barrier disruption, though no basal levels were obtained (significant for mBD-14 only).
Relative mRNA expression was quantified by real-time PCR (columns represent means±S.E. *Po0.05; n¼10–16). (b) Staining for mBD-1, -3, and -14 in
immunohistochemistry increased 6 hours after barrier injury by acetone treatment in SKH-1 mice. Staining density was reduced after artificial barrier repair
by latex occlusion. Bars¼ 50 mm. (c) Six hours after barrier disruption by acetone treatment, SKH-1 mice showed an increased protein staining for mBD-1, -3,
and -14 in western blot compared to untreated controls. b-Actin served as loading control.
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However, impairment of the permeability barrier by
scratches and other minor injuries is common and does not
necessarily result in skin infection. This indicates that
the skin has additional defense mechanisms. Several
studies have suggested that a major cutaneous defense
mechanism may be the inducible release of antimicrobial
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Figure 3. Expression of murine b-defensins (mBDs) is enhanced in metabolically barrier-disrupted skin and can be reduced by occlusion. (a) In metabolically
barrier-disrupted skin of mice fed an essential fatty acid–deficient (EFAD) diet, an increased mRNA expression was noted for mBD-1, -3, and -14 compared with
control mice fed a normal diet. Occlusion of EFAD mouse skin with a latex foil for 48 hours did significantly reduce the mRNA expression for all three mBDs
(columns represent means±S.E. *Po0.05; n¼11–12). (b) In EFAD mice, immunohistochemical staining density markedly increased for all three defensins.
Occlusion by a latex foil for 48 hours in EFAD mice caused reduction in staining intensity. Bars¼ 50 mm. (c) In EFAD mice all three investigated mBDs showed
an increase in protein staining in western blot. b-Actin served as loading control.
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peptides (Schro¨der and Harder, 2006; Schauber and Gallo,
2008).
To gain more insight into the role of antimicrobial peptides
upon barrier disruption, we used mouse models to investigate
the expression of mouse b-defensins mBD-1, -3, and -14—
orthologs of human defensins hBD-1, hBD-2, and hBD-3,
respectively—following skin barrier disruption. Acute stratum
corneum barrier injury can easily be caused by tape stripping
or acetone treatment, and the EFAD mouse is a model for
metabolically induced permeability barrier disruption
(Proksch et al., 1992). We found that barrier injury and
metabolically induced barrier dysfunction led to a slight to
moderate induction of mBD-1 and mBD-14 and a pro-
nounced increase in mBD-3 mRNA expression. An induction
of protein expression was confirmed by immunohistological
staining and western blotting, with highest induction for
mBD-3. Immunoreactivity for mBD-1, -3, and -14 in
unstimulated mouse epidermis was localized in the supraba-
sal layers with increased staining intensity toward the outer
layers of the epidermis. In injury and metabolically induced
barrier-disrupted skin, staining was extended to the entire
epidermis, although staining intensity was still most
pronounced in the outer layers. This is in agreement with
the proposed function of b-defensins as defense molecules
against invading microorganisms and is in concordance with
findings for human orthologs (Liu et al., 1998, 2002; Sørensen
et al., 2006; Jensen et al., 2007; Harder et al., 2010). These
results are also in line with a recent study showing
upregulation of mBD-3 and CRAMP (cathelin-related anti-
microbial peptide) expression after acute skin barrier injury
(Aberg et al., 2008).
Although there is a global increase in b-defensin expres-
sion after barrier injury, there are differences in the level of
induction. In contrast to the slight to moderate induction of
mBD-1 and mBD-14, we observed a pronounced induction
of mBD-3 after barrier injury. The upregulation of mBD-1
upon barrier injury was unexpected, because mBD-1 and the
human ortholog hBD-1 are generally considered constitu-
tively expressed b-defensins that are not induced by infection
or inflammation (Zhao et al., 1996; Morrison et al., 1998;
Mathews et al., 1999). The mechanism of mBD-1 (and
hBD-1) induction is unknown. In primary mouse keratino-
cytes stimulated with various cytokines and growth factors
upregulation of mBD-1 could not be observed (data
not shown).
Previous publications showed that the expression of
mBD-3 is induced by inflammation and infection (Bals
et al., 1999; Burd et al., 2002). Thus, one can speculate that
the strong induction of mBD-3 after skin barrier disruption
may be mediated by an increased expression of proinflam-
matory cytokines stimulated by skin injury. The hypothesis
that the induction of b-defensins in barrier dysfunction may
be mediated via proinflammatory cytokines and growth
factors is supported by several studies reporting that proin-
flammatory cytokines and growth factors are of crucial
importance for the repair of the permeability barrier in
mouse skin in vivo (Wood et al., 1992; Liou et al., 1997;
Jensen et al., 1999). To further investigate this hypothesis, we
intraperitonally injected mice with a neutralizing anti-TNF-a
antibody before performing barrier disruption. This treatment
significantly reduced the increase in mBD-3 expression. This
indicates that TNF-a contributes to the induction of mBD-3
upon barrier injury.
It has been reported that sterile wounding induced
expression of hBD-3, the human ortholog of mBD-14, a
process that is mediated via activation of the EGFR (Sørensen
et al., 2006). The observation that expression of mBD-14
mRNA (Hinrichsen et al., 2008) and protein can be induced
by the EGFR ligand TGF-a in mouse keratinocytes in vitro
prompts the interesting hypothesis that increased levels of
TGF-a and other growth factors may mediate the induction of
mBD-14 after barrier disruption.
Artificial barrier restoration by occlusion with a latex foil
reduced the increase in b-defensin mRNA expression
although significantly only for mBD-14. It has been shown
that several biochemical mechanisms involved in barrier
repair can be reduced by artificial barrier repair (Proksch
et al., 1990). However, not all biochemical effects are
reduced; in particular, cytokine expression is reduced only
under certain circumstances. Wood et al. (1994) reported that
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Figure 4. TNF-a and TGF-a influenced the expression of murine b-defensins
(mBDs) in primary mouse keratinocytes in vitro. (a) Primary mouse
keratinocytes were stimulated with 10 ngml1 TNF-a for 6 and 16hours, and
mBD-3 mRNA expression was analyzed by real-time PCR. The mRNA
expression of mBD-3 was increased. Bars represent the relative mBD-3
transcript levels normalized to GAPDH transcript levels. Results are presented
as means ± standard errors (*Po0.05; n¼ 9). (b) Expression of mBD-14
protein in supernatants of primary mouse keratinocytes stimulated for
24 hours with TGF-a (50 ngml1) was measured by ELISA. The protein release
of mBD-14 was significantly increased after stimulation with TGF-a compared
with medium controls (*Po0.05; n¼ 9).
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occlusion does not lower cytokine mRNA levels after acute
barrier disruption. Similarly, we found a reduction only in
mBD-14 expression, and not for mBD-3, because the
expression of mBD-3 is induced by proinflammatory stimuli
such as TNF-a, whereas the expression of mBD-14 is induced
by TGF-a. Growth factor expression is partially blocked in
occluded skin barrier disruption (Liou et al., 1997). Wood
et al. showed that cytokine expression was reduced in EFAD
mice after occlusion. Consistent with this, we found
reduction of all three mBDs after occlusion in these mice.
In summary, we found increased expression of mBD-1, -3,
and -14 after mechanical and metabolic skin barrier
disruption in mouse skin. The increased expression may
reflect a defense response to protect the skin against harmful
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Figure 5. Treatment of mice with a tumor necrosis factor-a (TNF-a) neutralizing antibody before barrier disruption reduced induction of murine b-defensin-3
(mBD-3) expression. (a) To block the activity of TNF-a, a neutralizing anti-TNF-a antibody was intraperitoneally injected into SKH-1 mice 24 hours before
barrier disruption by acetone treatment. Six hours later, the mRNA expression of mBD-3 was significantly reduced in mice treated with anti-TNF-a antibody
compared with mice treated with phosphate-buffered saline. No significant difference was recognized in the expression of mBD-1 and mBD-14 mRNA. Relative
mRNA expression was quantified by real-time PCR (columns represent means±SE. *Po0.05; n¼ 6). (b) Immunohistochemical analyses of skin samples from
mice treated with anti-TNF-a antibody showed a reduction of b-defensin protein staining, most pronounced for mBD-3. Bars¼ 50 mm.
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microorganisms that can invade skin with a dysfunction of
the permeability barrier.
MATERIALS AND METHODS
Mice
SKH-1 mice (Crl:(hr/hr) BR) were supplied by Charles River (Sulzfeld,
Germany). BALB/c mice were bred in the central animal facility at
the University of Kiel. For purposes of investigating barrier
disruption, male 6- to 8-week-old mice were used. EFAD mice
were obtained by feeding 3-week-old SKH-1 mice an EFAD diet
(Bavandi et al., 1992), modified by adding MgSO4 7H2O. Mice
were individually and conventionally maintained in plastic cages
under standardized conditions (room temperature 25 1C, relative
humidity 45–55%, circadian rhythm 12hours, and standard labora-
tory animal chow (V1534, SSNIFF Spezialdia¨ten, Soest, Germany)
and water supplied ad libitum. The University of Kiel Committee for
Animal Care approved the study.
Barrier injury of mouse skin and artificial barrier repair
The barrier of one flank of mouse skin was disrupted by repeated
tape stripping (cellophane tape) or by application of acetone with a
small cotton stick until a six- to eightfold increase in transepidermal
water loss (Tewameter TM 210, Courage & Khazaka, Cologne,
Germany) occurred. In one set of animals, the disrupted skin barrier
was immediately occluded with a latex foil after treatment. Hairy
mice were shaved with a razor blade 1 day before treatment. EFAD
mice were compared with a normally fed control group and
occluded for 48 hours.
Injection of neutralizing anti-TNF-a antibody in mice
To evaluate a possible role for TNF-a in induction of b-defensins, a
neutralizing anti-TNF-a antibody (0.5mg in phosphate-buffered
saline (PBS); eBioscience, Frankfurt, Germany, MP6-XT3) was
intraperitoneally injected into SKH-1 mice 24 hours before acetone
treatment. Control mice were injected with PBS.
Cell culture and stimulation
Primary keratinocytes were isolated from the skin of 1- to 2-day-old
BALB/c mice and cultivated in EpiLife-Medium (Sigma, Taufkirchen,
Germany) in collagenized six-well culture plates (9.6 cm2 per well;
Sarstedt, Nu¨rnbrecht, Germany) under standardized conditions
(37 1C, 0.5% CO2). Cells were stimulated at a confluence of
90–100%.
mRNA isolation, reverse transcription, and real-time PCR
mRNA isolation from cultured primary keratinocytes was performed
using the NucleoSpin RNA II Kit (Macherey-Nagel, Du¨ren,
Germany). Skin samples were minced in liquid nitrogen, and RNA
was isolated using the TRIzol reagent (Invitrogen, Karlsruhe,
Germany). Reverse-transcription reagents were obtained from
Applied Biosystems (HighCap cDNA RT Kit; Darmstadt, Germany).
cDNA was analyzed by real-time PCR (LightCycler 2.0; Roche
Diagnostics GmbH, Mannheim, Germany) using the SYBR Advan-
tage qPCR Premix (TaKaRa Bio Europe, Saint-Germain-en-Laye,
France). cDNA corresponding to 10 ng RNA was used as a template.
Samples were incubated for an initial denaturation at 95 1C for
10minutes followed by 45 cycles, each cycle consisting of 95 1C for
10 seconds, 60 1C (touchdown of 1 1C per cycle from 66 1C to
60 1C) for 5 seconds, and 72 1C for 15 seconds. To confirm
amplification of specific transcripts, melting curve profiles were
produced. (See Supplementary Table 1 online for a list of real-time
PCR primers (Eurofins MWG Operon, Ebersberg, Germany).)
Quantifications were normalized to the housekeeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Relative
expression is given as the ratio between target gene expression
and GAPDH expression.
Generation of mBD-14-specific antibodies
Expression of recombinant mBD-14 protein was described pre-
viously (Hinrichsen et al., 2008). In the present study, a fusion
protein (2.2mg) was used for immunization. This (1.5mg) was
conjugated to keyhole limpet hemocyanine (Sigma) using glutar-
aldehyde. Keyhole limpet hemocyanine (1mg) in 1ml PBS was
mixed with 1ml 25% glutaraldehyde (Serva, Heidelberg, Germany)
and incubated for 1 hour at room temperature with gentle shaking.
The reaction mixture was diafiltrated and concentrated in 400 ml
PBS using a Vivaspin 0.5ml concentrator column (30 kDa cutoff,
Vivascience, Hannover, Germany). The concentrate was incubated
with 600ml (1.5mg) mBD-14 fusion protein in PBS for 1 hour at
room temperature with gentle rotation. The reaction was stopped
by the addition of 5 ml 1M Tris (pH 8.0). mBD-14 fusion protein
(0.7mg) in 500 ml of PBS was added. The preparation was divided
into one 450ml aliquot for initial immunization and three 350ml
aliquots for booster immunization of a goat. Immunization was
carried out by ZIKA-Kaninchenbetrieb (Gottin, Germany). We
generated an mBD-14 affinity column (1ml HiTrap NHS-activated
columns, Amersham Pharmacia Biotech, Vienna, Austria) using
500mg recombinant mBD-14 to selectively isolate mBD-14-specific
antibodies from the serum. Also, a pET-32 affinity column using
650mg pET-32 was generated to remove pET-32-specific antibodies.
The mBD-14 affinity column was loaded with 750 ml goat anti-mBD-
14 serum and washed with 10mM sodium phosphate buffer, pH 7.4.
Low-affinity antibodies were eluted using 1M NaCl (pH 7), and high-
affinity mBD-14 antibodies were eluted using 200mM glycine (pH
3), immediately neutralized with 1M Tris (pH 7.5) and dialyzed
against PBS. Antibodies with affinity to pET-32 were removed
by pET-32 affinity column. Specificity of mBD-14 antibodies was
verified by immunohistochemistry and western blotting.
Western blot analysis
Peptides were extracted from mouse skin using a lysis buffer
containing 62.5M Tris, 5% SDS, and 10mM DTT. Proteins were
separated by 16.5% SDS-tricine polyacrylamide gel containing 6M
urea (Scha¨gger and von Jagow, 1987). Proteins were transferred to a
nitrocellulose membrane (0.2 mm, Amersham Hybond-ECL, GE
Healthcare, Freiburg, Germany), blocked for 1 hour in blocking
buffer (5% (wt/vol) BSA in PBSþ 0.05% Tween), then incubated
overnight at 4 1C in 3% (wt/vol) BSA in PBSþ 0.05% Tween
containing 1:250 anti-mBD-1 antibodies, 1:250 anti-mBD-3 anti-
bodies (both Santa Cruz Biotechnology, Santa Cruz, CA), or
1:10,000 mBD-14 affinity-purified antibodies (1.85mg/ml). The
membrane was washed with PBSþ 0.05% Tween six times for
5minutes each and incubated for 1 hour in 3% (wt/vol) BSA in
PBSþ 0.05% Tween containing 1:20,000 dilution of goat anti-rabbit
or rabbit anti-goat IgG HRP conjugate (Dianova, Hamburg,
Germany). After another six washes, the membrane was incubated
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for 5minutes with chemiluminescent peroxidase substrate
(Lumi-Light PLUS Western Blotting Substrate, Roche Diagnostics,
Mannheim, Germany) and visualized using a Diana III cooled
CCD-camera imaging system (Raytest, Straubenhardt, Germany).
b-Actin served as loading control in all western blots.
Immunohistochemistry
For immunohistochemistry, 5mm vertical paraffin sections were
deparaffinized and rehydrated followed by heat-induced antigen
retrieval in citrate acid buffer (10mM, pH 6.0). Slides were incubated
with 3% aqueous H2O2 for 5minutes at room temperature to block
endogenous peroxidase activity. After blocking nonspecific antibody
binding by incubation with normal rabbit or swine serum (1:5 in
Tris-buffered saline, Dako Diagnostics, Hamburg, Germany), sec-
tions were incubated with antibodies for mBD-1, mBD-3 (1:100,
both Santa Cruz Biotechnology), and mBD-14 (1.85mgml1, 1:100)
diluted in Tris-buffered saline (0.15M NaCl, 0.05M Tris, pH 7.6)
overnight at 4 1C. Sections were incubated for 30minutes with
secondary biotinylated antibodies (Dianova, Hamburg, Germany)
followed by incubation for 30minutes with StreptABComplex/HRP
(Dako Diagnostics), developed with Liquid DAB (Biogenex, San
Ramon, CA), and counterstained with Mayer’s hemalaun (Merck,
Darmstadt, Germany).
ELISA
Ninety-six-well immunoplates (MaxiSorp, Nunc, Roskilde, Denmark)
were coated at 4 1C overnight with 50 ml anti-mBD-14 antibody
diluted 1:2,000 to 1mgml1 in 0.05M carbonate buffer, pH 9.6.
Wells were blocked with 200ml 1% BSA in PBS for 10minutes
at 37 1C. After being washed three times with 200ml PBSþ 0.1%
Tween 20, 50ml cell culture supernatants and serial dilutions
of recombinant mBD-14 protein were incubated for 30minutes
at 37 1C. Plates were washed three times and incubated for
30minutes at 37 1C with 50ml biotinylated anti-mBD-14 antibody
diluted 1:4,000 to 0.23mgml1 in PBSþ 0.1% Tween 20. Plates
were washed again three times, filled with 50ml Streptavidin-POD
(Roche Diagnostics; 1:10,000 in PBSþ 0.1% Tween 20) and
incubated for 30minutes at 37 1C, washed six times, and incubated
with 2,29-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid (Roche
Diagnostics) for 30–45minutes at 37 1C. Absorbance was measured
at 405 nm with a multichannel photometer (Sunrise; Tecan,
Crailsheim, Germany).
Statistical analysis
All calculations were performed using the unpaired Student’s
t-test.
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